Title: Taxpayer Research and Coronavirus Knowledge Act of 2020
Policy area: Health

Summary:
Taxpayer Research and Coronavirus Knowledge Act of 2020
This bill requires the Department of Health and Human Services (HHS), in coordination with specified federal agencies, to compile a public, searchable database of federal contracts, tax benefits, and other support for COVID-19 (i.e., coronavirus disease 2019) biomedical research and development, including information regarding the source and amount of such support. HHS must develop the database within one month and update it every two weeks.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7288 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 7288

To direct the Secretary of Health and Human Services and other Federal 
officials to compile into a searchable database information relating to 
  Federal support for biomedical research and development related to 
                   COVID-19, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 22, 2020

 Mr. Doggett (for himself, Mr. Rooney of Florida, Ms. Schakowsky, Ms. 
   DeLauro, Mr. DeFazio, Mr. Pocan, and Ms. Jayapal) introduced the 
   following bill; which was referred to the Committee on Energy and 
    Commerce, and in addition to the Committees on Armed Services, 
 Veterans' Affairs, Science, Space, and Technology, the Judiciary, and 
   Ways and Means, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To direct the Secretary of Health and Human Services and other Federal 
officials to compile into a searchable database information relating to 
  Federal support for biomedical research and development related to 
                   COVID-19, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Taxpayer Research and Coronavirus 
Knowledge Act of 2020''.

SEC. 2. DATABASE.

    (a) In General.--The Secretary of Health and Human Services, the 
Director of the National Institutes of Health, the Assistant Secretary 
for Preparedness and Response of the Department of Health and Human 
Services, the Director of the Biomedical Advanced Research and 
Development Authority, the Secretary of Defense, the Secretary of 
Veterans Affairs, the Director of the National Institute of Allergy and 
Infectious Diseases, and such other Federal officials as the Secretary 
of Health and Human Services determines to be relevant, acting in 
coordination, shall--
            (1) compile into a searchable database information relating 
        to Federal support (before or after the date of enactment of 
        this Act) for biomedical research and development related to 
        COVID-19 (including biomedical research and development 
        relating to a product or therapy that was later modified or 
        repurposed to be used for COVID-19); and
            (2) make such database available on the public website of 
        the Department of Health and Human Services.
    (b) Covered Information.--The information relating to Federal 
support referred to in subsection (a)(1) includes all contracts, 
funding agreements, licensing arrangements, other transactions, and 
other arrangements entered into by the Federal Government and tax 
benefits provided with respect to research and development, and 
manufacturing, of a drug (including biological products), cell or gene 
therapy, or medical device intended to be manufactured, used, designed, 
developed, modified, repurposed, licensed, or procured to diagnose, 
mitigate, prevent, treat, or cure COVID-19, including but not limited 
to the following:
            (1) Licensing agreements pursuant to section 207 of title 
        35, United States Code.
            (2) Cooperative research and development agreements and 
        licensing agreements pursuant to section 3710a of title 15, 
        United States Code.
            (3) Funding agreements, as defined under section 201 of 
        title 35, United States Code.
            (4) Other transactions entered into pursuant to the 
        following statutes:
                    (A) Section 319L of the Public Health Service Act 
                (42 U.S.C. 247d-7e).
                    (B) Section 105 of the National Institutes of 
                Health Reform Act of 2006 (42 U.S.C. 284n).
                    (C) Section 480 of the Public Health Service Act 
                (42 U.S.C. 287a).
                    (D) Section 421 of the Public Health Service Act 
                (42 U.S.C. 285b-3).
                    (E) Section 2371 of title 10, United States Code.
            (5) Tax credits and deductions associated with--
                    (A) qualified clinical testing expenses, as defined 
                under section 45C of title 26, United States Code;
                    (B) qualified research expenses, as defined under 
                section 41 of title 26, United States Code; and
                    (C) charitable contributions, as defined under 
                section 170(c) of title 26, United States Code, to 
                patient assistance programs.
    (c) Information Required.--Notwithstanding any other provision of 
law, the Federal officials referred to in subsection (a) shall include 
in the database under subsection (a), with regard to each contract, 
funding agreement, licensing arrangement, other transaction, other 
arrangement, or tax benefit described in subsection (b), at least the 
following information:
            (1) The agency, program, institute, or other Federal 
        Government entity providing the Federal support.
            (2) The amount and period of Federal financial support with 
        an itemized breakdown.
            (3) Other Federal nonfinancial support, including but not 
        limited to the use of Federal personnel, Federal facilities, 
        and Federal equipment.
            (4) The grant number, if applicable.
            (5) Associated clinical trial data, upon trial completion.
            (6) Associated patents and patent applications, 
        specifying--
                    (A) any Federal ownership in such patents and 
                patent applications;
                    (B) the expiration date of such patents and filing 
                dates of such patent applications; and
                    (C) the numbers of such patents and patent 
                applications.
            (7) Associated periods of marketing exclusivity under 
        Federal law and the durations of such periods.
            (8) The corporation, nonprofit organization, academic 
        institution, person, or other entity receiving the Federal 
        support.
            (9) Any products (including repurposed products) approved, 
        authorized, or cleared for marketing, or for which marketing 
        approval, authorization, or clearance is being sought, the 
        development of which was aided by Federal support, including--
                    (A) the names of such products;
                    (B) the prices of such products; and
                    (C) the current and anticipated manufacturing 
                capacity to produce such products.
            (10) The full terms of the contract, funding agreement, 
        licensing arrangement, other transaction, or other arrangement 
        described in subsection (b).
    (d) Format of Information.--The database under subsection (a) shall 
be--
            (1) searchable and filterable according to the categories 
        of information described in subsection (c); and
            (2) presented in a user-friendly format.
    (e) Timing.--The database under subsection (a) shall be--
            (1) made publicly available not later than 1 month of the 
        date of enactment of this Act; and
            (2) updated not less than every 2 weeks.
    (f) Disclosure.--
            (1) In general.--Notwithstanding any other provision of 
        law, to the extent necessary for an official referred to in 
        subsection (a) to carry out this section, such official may 
        require entities receiving Federal support referred to in 
        subsection (a)(1) to disclose to the official any information 
        relating to such Federal support and required to be included in 
        the database under subsection (a).
            (2) Penalty for nondisclosure.--If an entity that is 
        required to disclose information pursuant to paragraph (1) 
        fails to disclose such information within a reasonable period 
        of time or within two weeks of the official requesting such 
        information, whichever is sooner, then such entity and all 
        executive officers employed by such entity shall no longer be 
        eligible for the receipt of Federal support in the form of a 
        contract, funding agreement, licensing arrangement, other 
        transaction, or other arrangement.
                                 <all>